Eye Med for Macular Adhesion
Age-related adhesions in the eye can lead to what scientists call a "macular hole." The standard treatment is surgery, but it's not without risks. Now researchersled byJulia Haller MD of the Wills Eye Institute in Philadelphia have conducted a trial with an injectable drug called ocriplasmin. They published their study in the Aug. 16 issue of the New England Journal of Medicine, reporting that "Intravitreal injection of the vitreolytic agent ocriplasmin resolved vitreomacular traction and closed macular holes in significantly more patients than did injection of placebo."
They also wrote that any "ocular adverse events" were "mainly transient." According to MedPage Today, Haller and colleagues cautioned that "these gains in visual acuity and in quality of life were modest, but that may have been due to the fact that the trials included patients with relatively good visual acuity at baseline." MedPage Today also notes that during a July meeting, an FDA advisory committee voted unanimously to recommend approval of ocriplasmin. A final decision is expected by Oct. 17.